Angamuthu Selvapandiyan | Professor
Jamia Hamdard
Dr. A. Selvapandiyan has been a prominent figure in vaccine development, with over 35 years of experience post-Ph.D. in molecular biology, focusing on molecular cell biology, diagnostics, immunology, and vaccinology. He has served as a Senior Research Scientist at the International Centre for Genetic Engineering and Biotechnology (UNIDO organization) in Delhi (1988-1999), a Visiting Scientist at the FDA USA (1999-2009), and as Team Lead and Professor (currently) at the Department of Molecular Medicine, Jamia Hamdard, Delhi. A significant achievement includes developing a gene-deleted live attenuated vaccine against visceral leishmaniasis, a severe parasitic disease, during his time at the US FDA. Since then, this vaccine candidate has undergone numerous experimental and preclinical studies in animals, with findings published in journals and protected by patents. Having successfully passed animal toxicity studies, the vaccine is poised to progress beyond the concept stage, demonstrating Dr. Selvapandiyan's substantial impact on vaccine innovation.
Appearances:
Pre-Congress Workshops - 21st April @ 14:00
GLOBAL HEALTH - PARASITIC & NTD VACCINES
Parasitic disease vaccine development short talks:
- Hookworm anaemia and malaria combination vaccine development
- Early development of a vaccine against visceral leishmaniasis
- A defined molecular vaccine for intestinal schistosomiasis * title TBC
- Development of vaccines for lymphatic filariasis *Title TBC
Panel: Challenges in establishing correlates of protection and planning trials for NTD (parasitic) vaccines
- What are the difficulties in establishing COP for parasitic vaccines
- Planning for ph2-3 trials – how can we innovate in creating pathways and designs?
Panel: Moving the needle: alternative pathways to approval for global health vaccines (Parasitic & Neglected Diseases)
- Considering pathways to approval in different scenarios – in-country experiences
- Enabling different technology pathways
- From a manufacturing perspective
- Moving from science to deployment – other than strong data what do we need to move these vaccines forward?
- Understanding incentives for production, government incentives to buy, individual country policies and regulatory requirements
- How is this challenge further compounded with diseases that are not fatal but have high morbidity burden?
- Case studies – Marburg, Hookworm
- Improving stringency of regulatory agencies through new frameworks
- Can combinations deal with the issue of high burden but low interest? What would be the complications of combining these types of vaccines?
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events